Clinical & Experimental Allergy, 42, 775–781
doi: 10.1111/j.1365-2222.2011.03945.x
ORIGINAL ARTICLE
Clinical Allergy
© 2011 Blackwell Publishing Ltd
Associated demographics of persistent exhaled nitric oxide elevation in
treated asthmatics
K. Matsunaga1, S. Yanagisawa1, T. Hirano1, T. Ichikawa1, A. Koarai1, K. Akamatsu1, H. Sugiura1, Y. Minakata1, K. Matsunaga2,
T. Kawayama2 and M. Ichinose1
1
Third Department of Internal Medicine, School of Medicine, Wakayama Medical University, Wakayama and 2Department of Medicine, Kurume University,
Fukuoka, Japan
Clinical &
Experimental
Allergy
Correspondence:
Masakazu Ichinose, Third Department
of Internal Medicine, School of
Medicine, Wakayama Medical
University, 811-1 Kimiidera,
Wakayama 641-8509, Japan.
E-mail: masakazu@wakayama-med.
ac.jp
Cite this as: K. Matsunaga,
S. Yanagisawa, T. Hirano, T. Ichikawa,
A. Koarai, K. Akamatsu, H. Sugiura,
Y. Minakata, K. Matsunaga,
T. Kawayama and M. Ichinose, Clinical
& Experimental Allergy, 2012 (42)
775–781.
Summary
Background The fraction of exhaled nitric oxide (FENO) is reduced by anti-inflammatory
treatment in asthma. However, the FENO level is also regulated by individual demographics and there is considerable variation among clinically stable patients.
Objective We hypothesized that some demographics may be responsible for persistent
FENO elevation despite inhaled corticosteroids (ICS) therapy in asthma.
Methods This was a prospective observational study. We initially screened 250 stable
asthmatics and determined the FENO cut-off point for identifying poorly controlled
asthma defined by one of the following criteria: Asthma control test <20, or forced expiratory volume in one-second % of predicted <80%, or peak expiratory flow variability
<80% (Study 1). After 12-weeks, 229 patients who maintained high or low FENO were
selected and the independent factors which might contribute to a high FENO were examined (Study 2).
Results A FENO level >39.5 p.p.b. yielded 67% sensitivity and 76% specificity for identifying the patients with poorly controlled asthma. The persistent high FENO group (40 p.
p.b.) was more likely to be ex-smokers, to show evidence of atopy (positive specific IgE,
higher serum IgE and blood eosinophils), and to have allergic comorbidities. Especially,
past smoking history, blood eosinophils, and chronic rhinosinusitis were identified to be
independent predictors of high FENO. Neither the dose of ICS nor other medication use
showed any difference between the groups.
Conclusions and Clinical Relevance These results suggested that past smoking history,
blood eosinophilia, and chronic rhinosinusitis are involved in the persistent airway
inflammation detected by FENO. Although their relative contributions on FENO values
should be further quantified, clarification of the features of the subjects with high FENO
might provide clues for adjustment of the treatment approach in asthma.
Keywords airflow obstruction, airway lability, allergic rhinitis, chronic rhinosinusitis,
eosinophil, gastro-esophageal reflux disease, immunoglobulin E, inhaled corticosteroids,
smoking
Abbreviations ACT, asthma control test; CRS, chronic rhinosinusitis; FENO, exhaled nitric
oxide fraction; GERD, gastro-esophageal reflux disease; ICS, inhaled corticosteroids; NOS,
nitric oxide synthases.
Submitted 06 September 2011; revised 08 November 2011; accepted 13 December 2011
Introduction
Airway inflammation is a central features of asthma,
and inhaled corticosteroids (ICS) are widely used for the
long-term management of the disease [1]. Nitric oxide
(NO) is a gaseous signalling molecule that is generated
by NO synthases (NOS). The expression of inducible
NOS is enhanced by inflammatory stimuli producing
large amounts of NO independently of calcium ion flux
[2]. Indeed, the exhaled nitric oxide fraction (FENO) is
776 K. Matsunaga et al
elevated in asthma [3] and is reduced in a dose-dependent manner by treatment with ICS [4]. However, the
FENO is also influenced by individual characteristics
such as height, gender, atopy, rhinitis, and smoking status [5–8]. These confounders are considered to be a
major limiting factor for the implementation of FENO
measuring as a guide for asthma management [7–10].
Recent studies have shown that sequential changes in
FENO are indicative of the loss of asthma control even
in smokers and patients with atopy [9, 10], suggesting
that sequential FENO measuring may improve asthma
management even in the subjects with confounders.
However, not all patients with asthma respond to corticosteroids similarly [11] and there is considerable variation in the levels of FENO among clinically stable
patients. Indeed, the FENO remains persistently high
despite ICS treatment in some individuals. A recent
study has shown that the grouping of asthma by FENO
provides an independent classification of asthma severity and the subgroups with high FENO are the most
reactive and worrisome phenotype [12]. There is also
evidence that increased FENO is associated with the loss
of asthma control [13, 14] and accelerated decline in
pulmonary function [15]. However, it has not been fully
elucidated whether or not any patient factors are
associated with the persistent FENO elevation in asthma.
In the present study, we hypothesized that some factors may be responsible for high FENO despite ICS
treatment. It is well known that the FENO values are
modified by asthma control and steroid therapy [16].
All study participants were stable following ICS therapy
and the subjects with recent exacerbations of asthma
were excluded to control these modifiers. Because the
upper limit of the FENO level in patients with stable
asthma is still controversial [5, 12, 17, 18], we initially
determined the cut-off point for high FENO on the basis
of variables for asthma control including asthma control test (ACT), forced expiratory volume in one-second
(FEV1), and peak expiratory flow (PEF) variability
(Study 1). After 12-weeks observation, the patients who
maintained high or low FENO were selected and the
independent factors which might contribute to the
persistent FENO elevation were investigated (Study 2).
Methods
including smoking history, medication use, and comorbidities such as atopy, allergic rhinitis, chronic rhinosinusitis (CRS), or gastro-esophageal reflux disease
(GERD) were obtained.
Study subjects
All subjects were recruited from June 2010 to August
2010 to avoid the influence of the cedar pollen season
in Japan. Subjects over 20 years old were eligible if
they satisfied the standard criteria for asthma [18]. All
patients were stable following the treatment of ICS with
or without inhaled long-acting b2-agonist, leukotriene
receptor antagonist, or theophylline. Subjects were
excluded if they were current smokers, had had an
exacerbation of asthma, or had been treated with systemic steroids during and/or 8-weeks prior to the study.
Also, patients with poor adherence to the treatment or
with other pulmonary diseases were excluded. All
ex-smokers and patients with CRS had chest computed
tomography to exclude clinically occult emphysema or
bronchiectasis. Specific IgE for fungus and anti-neutrophil cytoplasmic antibody was examined to exclude
allergic bronchopulmonary aspergillosis or allergic
granulomatous angitis at the discretion of the
physician.
All comorbidities were identified by specialists on the
basis of guidelines [19, 20]. We considered that the
presence of nasal polyps by endoscopy and sinus mucosal changes by computed tomography is essential for
the diagnosis of CRS because CRS with nasal polyps is
characterized by intense eosinophilic inflammation and
Th2 polarization [19]. Complete blood cell count, differential count of leucocytes, total serum immunoglobulin
E (IgE) levels, and specific IgE for common inhaled
allergens (housedust, mite, cedar, cypress, ragweed,
cocksfoot, dog, and cat) were examined. Positive
specific IgE to at least one allergen was assumed to
confirm atopy. This study was approved by the local
ethics committee, and informed written consent was
obtained from each subject.
FENO measurement
The fraction of exhaled nitric oxide, FENO was measured by an online electrochemical NO analyser (NIOX
Study design
This was a prospective observational study for investigating the relationship between patient factors and the
persistent FENO elevation in asthma (Fig. 1). PEF measurement was done at least 8-weeks prior to the study
and pulmonary function test, ACT, and the FENO levels
were assessed before and 12-weeks after the observation without changes in the treatment. Medical records
Fig. 1. Study design.
© 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 42 : 775–781
Determinants of high exhaled nitric oxide in asthma
MINO; Aerocrine AB, Solna, Sweden) as previously
described [8]. The subjects exhaled at a constant flow
rate of 50 mL/s. Exhalations were repeated to obtain
two acceptable measurements within 10% deviation,
and the average of these two values was registered.
Pulmonary function and ACT measurement
The forced vital capacity (FVC) and FEV1 were measured as previously described [8]. The morning PEF was
monitored and the lowest pre-bronchodilator PEF over
a week, expressed as a percentage of the highest PEF
(Min%Max), was assumed to represent the PEF variability [21]. The ACT is a questionnaire that assesses the
asthma condition according to five items, each of which
can be rated on a five point scale [22]. A validated
Japanese translation was used.
Determination of cut-off point for FENO levels
The rationale for selecting the cut-off point for high
and low FENO was based on previous reports [17, 18]
and on a sub-analysis of the data collected during the
screening period (Study 1). Using the ROC curve
method, we determined the FENO cut-off point for
identifying poorly controlled asthma defined by one of
the following criteria: ACT score <20, or FEV1% of
predicted <80%, or Min%Max <80%.
Statistical analysis
All data were expressed as mean values ±SD for continuous variables. For categorical variables, the numbers
of observations and percentages were given in each category. Comparisons between different subgroups were
performed by Fisher’s exact test and Kruskal–Wallis
test. Multivariate logistic regression analysis was used
to assess the association between the binary outcome
(FENO 40 p.p.b.) and a set of demographic covariates. The variables with P-values <0.20 in the univariate analysis were included in the multivariate model.
Spearman’s correlation analysis was performed to assess
the correlation between the number of eosinophils in
the blood and the FENO level. A P-value of < 0.05 was
considered significant.
777
(Fig. 2). Thus, we selected 40 p.p.b. as the cut-off point
for high and low FENO in the subsequent analysis, a
value that was within previously published cut-off
points ranging from 35 to 50 p.p.b. [17, 23].
After 12-weeks observation, 229 patients who maintained high or low FENO were selected (Table 1). Of the
21 dropouts, nine subjects in the high FENO group and
six subjects in the low FENO group were switched over
to the other group. Other dropouts were related to either
exacerbations of asthma or non-adherence. The selected
subjects were divided into the low FENO group
(n = 158, 69.0%) and the high FENO group (n = 71,
31.0%) (Table 2). The baseline FVC and %FVC were
similar between the groups, although the FEV1/FVC
ratio (P < 0.005) and %FEV1 (P < 0.001) were significantly lower in the high FENO group. The high FENO
group had more exaggerated fluctuations of airway calibre (Min%Max), and more severe symptoms of asthma
(ACT) (all P < 0.001).
Next, the relationships between the FENO levels and
patient demographics were examined (Table 3). Compared to the low FENO group, the subjects with high
FENO were more likely to be ex-smokers (low FENO,
21.5%; high FENO 52.1%; P < 0.001), although there
was no significant difference in pack-years between the
groups (P = 0.39). Furthermore, the asthmatics with high
FENO were more likely to show evidence of atopy such
as positive specific IgE (low FENO, 70.2%; high FENO
91.5%; P < 0.01), higher serum IgE (P < 0.001) and
blood eosinophils (P < 0.001), and to have allergic comorbidities such as allergic rhinitis (low FENO, 60.8%; high
FENO 87.3%; P < 0.001), and CRS (low FENO, 7.6%; high
FENO 54.9%; P < 0.0001). Gender and leukotriene receptor antagonist use tended to be associated with high
FENO (P < 0.1) but it was not significant.
Results
During the screening period, the variables for asthma
control were obtained from 250 patients, and 51
patients (22.3%) were defined as poorly controlled
asthma based on the following criteria: ACT < 20
(n = 16), or %FEV1 <80% (n = 29), or Min%
Max < 80% (n = 30). A FENO level >39.5 p.p.b. yielded
67% sensitivity and 76% specificity (AUC = 0.749)
© 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 42 : 775–781
Fig. 2. Receiver operating characteristics (ROC) curve to estimate the
FENO cut-off values for identifying poorly controlled asthma. Data
labels represent cut-off values of FENO (arrow), area under the curve
(AUC), sensitivity and specificity.
778 K. Matsunaga et al
Table 1. Characteristics of subjects who maintained high or low FENO
levels
Number (female/male)
Mean age (years)
Body mass index (kg/mm2)
Smoking status (Never : Ex), n (%)
Atopy, n (%)
Allergic rhinitis, n (%)
Chronic rhinosinusitis, n (%)
GERD, n (%)
Inhaled corticosteroids, n (%)
Inhaled long-acting b2 agonist, n (%)
Leukotriene receptor antagonist, n (%)
Theophylline, n (%)
FVC (L)
FVC % of predicted (%)
FEV1 (L)
FEV1% of predicted (%)
PEF variability (Min%Max) (%)
Blood eosinophils (cells/lL)
Serum IgE levels (IU/mL)
FENO (p.p.b.)
Asthma control test (points)
229 (133/96)
46.6 ± 14.7
22.5 ± 3.9
158 (69.0) : 71 (31.0)
176 (76.9)
158 (69.0)
51 (22.3)
31 (13.5)
229 (100.0)
99 (43.2)
43 (18.8)
19 (8.3)
3.53 ± 0.89
103.7 ± 13.0
2.71 ± 0.77
96.7 ± 15.9
87.5 ± 6.0
251 ± 209
530 ± 1496
34.6 ± 22.0
22.9 ± 2.2
GERD, gastro-esophageal reflux disease; FVC, forced vital capacity;
FEV1, forced expiratory volume in one-second; PEF, peak expiratory
flow; Min%Max, the lowest PEF over a week, expressed as the percentage of the highest PEF; IgE, immunoglobulin E; FENO, exhaled
nitric oxide fraction. Mean (SD) values are provided unless otherwise
indicated.
Table 2. Pulmonary function test and asthma symptom score by
exhaled nitric oxide levels
Characteristics
FVC (L)
FVC % of predicted (%)
FEV1 (L)
FEV1/FVC ratio (%)
FEV1% of predicted (%)
Minimal PEF (L/min)
Maximal PEF (L/min)
PEF variability
(Min%Max) (%)
Asthma control test
(points)
Low FENO
(<40 p.p.b.)
n = 158
High FENO
(40 p.p.b.)
n = 71
P-value
3.53
104.8
2.77
78.4
101.1
421
468
89.9
3.51
101.1
2.59
73.4
87.0
398
481
82.2
0.76
0.07
0.09
<0.005
<0.001
0.06
0.80
<0.001
±
±
±
±
±
±
±
±
0.91
13.2
0.77
9.6
15.0
113
123
4.3
23.5 ± 2.1
±
±
±
±
±
±
±
±
0.82
12.3
0.76
10.3
13.4
119
129
5.7
21.6 ± 2.0
<0.001
FENO, exhaled nitric oxide fraction; FVC, forced vital capacity; FEV1,
forced expiratory volume in one-second; PEF, peak expiratory flow;
Min%Max, the lowest PEF over a week, expressed as the percentage
of the highest PEF. Mean (SD) values are provided.
According to the multivariate logistic regression
analysis, blood eosinophilia and CRS were identified to
be independent predictors of high FENO (OR 1.78,
P < 0.0001, and OR 11.71, P < 0.0001 respectively)
(Table 4). In addition, a past smoking history was also
detected as an independent predictor of high FENO (OR
4.14, P < 0.005). Indeed, the FENO was significantly
higher for ex-smokers than that for never-smokers, and
subjects with CRS showed significantly higher levels of
FENO compared with subjects without CRS (all
P < 0.001). The number of eosinophils in the blood was
significantly associated with the FENO level (r = 0.57,
P < 0.0001) (Fig. 3).
Overall, 65 of 71 subjects (91.5%) with high FENO
had at least one of three factors including past smoking
history, CRS, and hypereosinophilia defined as a blood
eosinophil count >450/lL. Neither the dose of ICS nor
other medication use showed any difference between
the two groups (Table 3).
Discussion
The present study provides evidence that several factors
are responsible for persistent FENO elevation despite
ICS treatment in the patients with stable asthma. The
subjects with sustained high FENO were characterized
by lower %FEV1 values, exaggerated fluctuation of airway calibre, and more severe asthma symptoms. They
were more likely to be ex-smokers, to show evidence of
atopy, and to have allergic comorbidities. Interestingly,
past smoking history, blood eosinophilia, and CRS were
identified as independent predictors of persistent FENO
elevation in treated asthmatics.
An elevated FENO level is known to represent the
presence of airway inflammation [2, 4]. In some individuals, the FENO levels remain high despite adequate
conventional therapy [12, 24]. This was also found in
our study, and approximately 30% of the subjects had
sustained high FENO. This might be explained by the
presence of heterogeneous airway inflammation that is
relatively resistant to steroids [6, 25–27]. Recently, neutrophilic or persistent eosinophilic inflammation was
found in asthmatics with raised FENO despite steroid
therapy [25–27]. Furthermore, stepwise increases in ICS
or systemic steroids reduce the FENO levels to some
extent [28, 29], which might also reinforce this hypothesis. Because FENO measurement identified the subgroup of asthma with persistent airway inflammation,
irreversible changes of the airway structure could result
in airway obstruction and/or vulnerable airway conditions 12, 25–27]. The persistent high FENO might reflect
long-standing airway inflammation and its resultant
remodelling [13]. Alternatively, inadequate anti-inflammatory therapy may be a possible explanation for the
presence of the persistent FENO elevation. However, in
our study, neither the dose of ICS nor other medication
use showed any difference between the groups. In addition, neither inhalation instruction nor increasing the
ICS dose reduced the sustained high FENO in asthmatic
© 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 42 : 775–781
Determinants of high exhaled nitric oxide in asthma
779
Table 3. Subject demographics by exhaled nitric oxide levels
Characteristic
Low FENO (<40 p.p.b.)
n
High FENO (40 p.p.b.)
n
P-value
Mean age (years)
Gender (male), n (%)
Body mass index (kg/mm2)
Ex-smokers, n (%)
Pack-years (years)
Atopy, n (%)
Allergic rhinitis, n (%)
Chronic rhinosinusitis, n (%)
GERD, n (%)
Blood eosinophils (cells/lL)
Serum IgE levels (IU/mL)
Dose of inhaled corticosteroids (lg/day)*
Inhaled long-acting b2 agonist use, n (%)
Leukotriene receptor antagonist use, n (%)
Theophylline use, n (%)
46.1 ± 15.1
64 (40.5)
22.2 ± 3.8
34 (21.5)
17.7 ± 13.9
111 (70.2)
96 (60.8)
12 (7.6)
21 (13.3)
173 ± 135
390 ± 1281
344 ± 109
65 (41.1)
25 (15.8)
13 (8.2)
158
158
158
158
35
158
158
158
158
158
158
158
158
158
158
48.1 ± 13.9
32 (45.1)
23.4 ± 4.0
37 (52.1)
15.6 ± 9.5
65 (91.5)
62 (87.3)
39 (54.9)
10 (14.1)
420 ± 237
842 ± 1863
352 ± 107
34 (47.9)
18 (25.4)
6 (8.5)
71
71
71
71
36
71
71
71
71
71
71
71
71
71
71
0.38
0.07
0.14
<0.001
0.39
<0.01
<0.001
<0.0001
0.87
<0.001
<0.001
0.60
0.34
0.09
0.96
*Inhaled corticosteroids, expressed as fluticasone propionate equivalents. FENO, exhaled nitric oxide fraction; GERD, gastro-esophageal reflux
disease. Mean (SD) values are provided unless otherwise indicated.
r = 0.57
p < 0.0001
FENO (ppb)
100
10
10
100
1000
Blood Eosinophils (cells/μL)
Fig. 3. Relationship between the number of eosinophils in the blood
and the FENO levels: The line corresponds to the fitted regression
equation. The r- value was Spearman’s correlation coefficient.
Table 4. Multivariate logistic regression analysis with high exhaled
oxide (40 p.p.b.) as the outcome
All asthma (n = 229)
Characteristic
Odds ratio (95% CI)
P-value
Female
Body mass index
Ex-smokers*
Atopy
Allergic rhinitis
Chronic rhinosinusitis*
Log number eosinophils in the blood*
Log serum immunoglobulin E
Leukotriene receptor antagonist use
0.94
1.00
4.14
1.59
3.75
11.71
1.78
1.00
2.81
0.89
0.98
<0.005
0.56
0.08
<0.0001
<0.0001
0.82
0.09
(0.49–2.21)
(0.90–1.11)
(1.67–10.24)
(0.33–7.69)
(0.85–16.61)
(4.00–34.27)
(1.47–2.14)
(1.00–1.00)
(0.86–9.18)
*Independent predictors of persistently high exhaled nitric oxide
fraction.
children [24]. More than 90% of subjects with high
FENO had at least one of three factors including past
smoking history, CRS, and hypereosinophilia, which
© 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 42 : 775–781
suggests that persistent airway inflammation detected
by FENO is probably related to these factors.
Atopy and allergic comorbidities were identified as
contributing factors for the persistent high FENO. A significant increase in blood eosinophils was found in
treated asthmatics and positive correlations were found
between blood eosinophils and FENO levels [30], suggesting that an ongoing recruitment and activation of
inflammatory cells may be present in asthmatic airways
even when treated by ICS. It is known that eosinophils
could be one of the sources of the increased NO production [31] and NO production might be involved in
facilitating the migration of eosinophils [32]. Atopy has
been known to be associated with airway hyperresponsiveness [21] and asthma patients with atopy show significantly higher levels of FENO than non-atopic
patients [5, 7]. In addition, allergic rhinitis raises the
FENO significantly [8, 10], and nasal ICS therapy has
been reported to reduce the FENO in the patients suffering from asthma and rhinitis [33]. Although CRS was
also identified as a predictor for high FENO, it is
unclear why only this comorbidity could reach significance in the multivariate analysis. CRS is more often
associated with sputum eosinphilia [34] and with damage of the airway mucosa than the other diseases [35].
This additional airway inflammation might enhance the
production of exhaled NO. Our definition of CRS, which
included both sinus changes and nasal polyps, may
have led to the association we observed. Indeed, a
recent study showed that increased FENO is more frequent in CRS with nasal polyps compared with CRS
without nasal polyps [36]. Moreover, in our study, the
mean number of blood eosinophils was significantly
higher for subjects with CRS than that for subjects
without CRS (P < 0.0001), even though 62% of the lat-
780 K. Matsunaga et al
ter group had allergic rhinitis (data not shown). The
previous studies and ours suggest that the allergic comorbidities function as a potential reservoir of inflammatory mediators, and reciprocally influence the airway
inflammation.
There is no doubt that current smoking reduces the
FENO levels through reduced production and increased
consumption of NO [5, 8, 9]. However, the effects of
ex-smoking on the FENO remain to be elucidated.
Although steroids have a number of anti-inflammatory
actions including the suppression of inducible NOS
expression [1, 2], a history of smoking has been
reported to impair the effects of steroid therapy in
asthma [6, 37]. As shown in Table 3, approximately
half of the ex-smokers with asthma showed sustained
high FENO. These results suggest that past smoking
might have changed the airway condition resulting in
a more vulnerable and steroid resistant airway in some
ex-smokers with asthma. This phenomenon could be
partially explained by the fact that smoking potentially induces nitrative stress [6] and that excessive NO
synthesis was found in individuals with refractory
asthma [27]. Further study is needed to clarify the
long-standing influence of past smoking on airway
inflammation.
There would be some limitations in our study. First,
the observation period might be too short to select subjects who maintained high or low FENO. Second, a
selection bias is possible because the subjects with
symptoms suggestive of comorbidities including allergic
References
1 Barnes PJ, Pederson S, Busse WW.
Efficacy and safety of inhaled corticosteroids. New developments. Am J
Respir Crit Care Med 1998; 157:S1–53.
2 Saleh D, Ernst P, Lim S, Banes PJ,
Giaid A. Increased formation of the
potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide
synthase: effect of inhaled glucocorticoid. FASEB J 1998; 12:929–37.
3 Alving K, Weitzberg E, Lundberg JM.
Increased amount of nitric oxide in
exhaled air of asthmatics. Eur Respir J
1993; 6:1368–70.
4 Jatakanon A, Lim S, Kharitonov SA,
Chung KF, Barnes PJ. Correlation
between exhaled nitric oxide, sputum
eosinophils, and methacholine responsiveness in patients with mild asthma.
Thorax 1998; 53:91–5.
5 Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Toren K. Height, age,
6
7
8
9
10
rhinitis, CRS, and GERD were referred to a specialist.
Thus, the data set might not completely represent the
population with clinically occult comorbidities [19, 20,
34]. Third, we carefully avoided the cedar pollen season
in Japan, but perennial allegen might be a cause of sustained high FENO [23]. Finally, although all subjects
had been regularly educated on the correct medication
use, we could not verify adherence objectively. Poor
adherence could be an explanation for sustained high
FENO values in some subjects.
In conclusion, we have shown that past smoking history, blood eosinophilia, and chronic rhinosinusitis are
involved in the persistent airway inflammation detected
by FENO. Although their relative contributions on
FENO values should be furthermore quantified, clarification of the features of the subjects with high FENO
might provide clues for adjustment of the treatment
approach in asthma.
Acknowledgements
The authors thank Mr Brent Bell for reading the manuscript. All authors of this manuscript give condolences
to the co-researcher Professor Hisamichi Aizawa.
Sources of support: This work was supported by grant
H22-meneki-ippan-012 from the Ministry of Health,
Labor and Welfare, Japan.
Conflict of interest: No potential conflicts of interest
exist with any companies and organizations whose
products or services may be discussed in this article.
and atopy are associated with fraction
of exhaled nitric oxide in a large adult
general population sample. Chest
2006; 130:1319–25.
Barnes PJ, Adock IM. Glucocorticoid
resistance in inflammatory diseases.
Lancet 2009; 373:1905–17.
Scott M, Raza A, Karmaus W et al.
Influence of atopy and asthma on
exhaled nitric oxide in an unselected
birth cohort study. Thorax 2010;
65:258–62.
Matsunaga K, Hirano T, Akamatsu K
et al. Exhaled nitric oxide cut-off
values for asthma diagnosis according
to rhinitis and smoking status in Japanese subjects. Allergol Int 2011; 60:
331–7.
Michils A, Louis R, Peche R, Baldassarre S, Muylem V. Exhaled nitric
oxide as a marker of asthma control in
smoking patients. Eur Respir J 2009;
33:1295–301.
Papainoannou AI, Minas M, Tanou K,
Gourgoulianis KI, Kostikas K. Exhaled
11
12
13
14
NO may predict loss of asthma control: the effect of concomitant allergic
rhinitis. Eur Respir J 2009; 34:
1005–7.
Szefler SJ, Martin RJ. Lessons learned
from variation in response to therapy
in clinical trials. J Allergy Clin Immunol 2010; 125:285–92.
Dweik RA, Sorkness RL, Whenzel S
et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk
phenotype among patients with
asthma. Am J Respir Crit Care Med
2010; 181:1033–41.
Gelb AF, Flynn Taylor C, Shinar CM,
Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict
exacerbations in treated asthmatics.
Chest 2006; 129:1492–9.
Michils A, Baldassarre S, Van Muylem
A. Exhaled nitric oxide and asthma
control: a longitudinal study in unselected patients. Eur Respir J 2008;
31:539–46.
© 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 42 : 775–781
Determinants of high exhaled nitric oxide in asthma
15 van Veen IH, Ten Brinke A, Sterk PJ
et al. Exhaled nitric oxide predicts
lung function decline in difficult-totreat asthma. Eur Respir J 2008;
32:344–9.
16 Mahut B, Peiffer C, Thibaudon M et al.
What does a single exhaled nitric
oxide measurement tell us in asthmatic
children? J Asthma 2009; 46:810–4.
17 Smith AD, Cowan JO, Brassett KP,
Herbison GP, Taylor DR. Use of
exhaled nitric oxide measurements to
guide treatment in chronic asthma. N
Engl J Med 2005; 352:2163–73.
18 Matsunaga K, Hirano T, Kawayama T
et al. Reference ranges for exhaled
nitric oxide fraction in healthy Japanese adult population. Allergol Int
2010; 59:363–7.
19 Allergic Rhinitis and its Impact on
Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).
Allergy 2008;63 (Suppl 86):8–160.
20 American College of Gastroenterology.
Updated guidelines for the diagnosis
and treatment of gastroesophageal
reflex disease. Am J Gastroenterol
2005; 100:190–200.
21 Global initiative for asthma. Global
strategy for asthma management and
prevention: NHLBI/WHO Workshop
report. NHLBI 2006.
22 Nathan RA, Sorkness CA, Kosinski M
et al. Development of the asthma control test: a survey for assessing asthma
control. J Allergy Clin Immunol 2004;
113:59–65.
23 Dweik RA, Boggs PB, Erzurum SC
et al. An official ATS clinical practice
24
25
26
27
28
29
30
guideline: Interpretation of exhaled
nitric oxide levels (FENO) for clinical
applications. Am J Respir Crit Care
Med 2011; 184:602–15.
Pijnenburg MWH, Bakker EM, Lever S,
Hop WC, De Jongste JC. High fractional concentration of nitric oxide in
exhaled air despite steroid treatment in
asthmatic children. Clin Exp Allergy
2005; 35:920–5.
Silkoff PE, Lent AM, Busacker AA
et al. Exhaled nitric oxide identifies
the persistent eosinophilic phenotype
in severe refractory asthma. J Allergy
Clin Immunol 2005; 116:1249–55.
The ENFUMOSA Study Group. The
ENFUMOSA cross-sectional European
multicentre study of the clinical phenotype of chronic refractory asthma.
European Network for Understanding
Mechanisms of Refractory Asthma. Eur
Respir J 2003; 22:470–7.
Sugiura H, Komaki Y, Koarai A, Ichinose M. Nitrative stress in refractory
asthma. J Allergy Clin Immunol 2008;
121:355–60.
Perez-de-Llano LA, Carballada F, Castro Anon O et al. Exhaled nitric oxide
predicts control in patients with difficult-to-treat asthma. Eur Respir J
2010; 35:1221–7.
Little SA, Chalmers GW, MacLeod KJ,
McSharry C, Thomson NC. Non-invasive markers of airway inflammation
as predictors of oral steroid responsiveness in asthma. Thorax 2000;
55:232–4.
Strunk RC, Szefler SJ, Phillips BR et al.
Relationship of exhaled nitric oxide to
clinical and inflammatory markers of
© 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 42 : 775–781
31
32
33
34
35
36
37
781
persistent asthma in children. J Allergy
Clin Immunol 2003; 112:883–92.
del Pozo V, de Arruda-Chaves E, de
Anders B et al. Eosinophils transcribe
and translate messenger RNA for
inducible nitric oxide synthase. J
Immunol 1997; 158:859–67.
Thomazzi SM, Ferreira HH, Conran N,
de Nucci G, Antunes E. Role of nitric
oxide on in vitro human eosinophill
migration. Biochem Pharmacol 2001;
62:1417–21.
Ribeiro de Andrade C, Chatkin JM,
Fiterman J, Scaglia N, Camargos PA.
Unified disease, unified management:
treating allergic rhinitis and asthma
with nasally inhaled corticosteroid.
Respir Med 2010; 104:1577–80.
ten Brinke A, Grootendorst DC,
Schmidt JT et al. Chronic sinusitis in
severe asthma is related to sputum
eosinophilia. J Allergy Clin Immunol
2002; 109:621–6.
Rolla G, Colagrande P, Scappaticci E
et al. Damage of the pharyngeal
mucosa and hyperresponsiveness of
airway in sinusitis. J Allergy Clin
Immunol 1997; 100:52–7.
Guida G, Rolla G, Badiu I et al. Determintants of exhaled nitric oxide in
chronic rhinosinusitis. Chest 2010;
137:658–64.
Chaundhri R, Livingston E, McMahon
AD, Thomson L, Borland W, Thomson
NC. Cigarette smoking impairs the
therapeutic response to oral corticosteroids in chronic asthma. Am J Respir
Crit Care Med 2003; 168:1308–11.